These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20623073)

  • 1. Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.
    Sooriyaarachchi M; Gailer J
    Dalton Trans; 2010 Aug; 39(32):7466-73. PubMed ID: 20623073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remarkable effect of mobile phase buffer on the SEC-ICP-AES derived Cu, Fe and Zn-metalloproteome pattern of rabbit blood plasma.
    Jahromi EZ; White W; Wu Q; Yamdagni R; Gailer J
    Metallomics; 2010 Jul; 2(7):460-8. PubMed ID: 21072345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone chelation therapy for thalassemia major.
    Galanello R; Campus S
    Acta Haematol; 2009; 122(2-3):155-64. PubMed ID: 19907153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the plasma metalloproteome by SEC-ICP-AES: bridging proteomics and metabolomics.
    Manley SA; Gailer J
    Expert Rev Proteomics; 2009 Jun; 6(3):251-65. PubMed ID: 19489698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R; Piga A; Harmatz P; Nielsen P
    Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.
    Evans P; Kayyali R; Hider RC; Eccleston J; Porter JB
    Transl Res; 2010 Aug; 156(2):55-67. PubMed ID: 20627190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simultaneous Cu-, Fe-, and Zn-specific detection of metalloproteins contained in rabbit plasma by size-exclusion chromatography-inductively coupled plasma atomic emission spectroscopy.
    Manley SA; Byrns S; Lyon AW; Brown P; Gailer J
    J Biol Inorg Chem; 2009 Jan; 14(1):61-74. PubMed ID: 18781345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone.
    Lai ME; Grady RW; Vacquer S; Pepe A; Carta MP; Bina P; Sau F; Cianciulli P; Maggio A; Galanello R; Farci P
    Blood Cells Mol Dis; 2010 Aug; 45(2):136-9. PubMed ID: 20678715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Probing the interaction of arsenobetaine with blood plasma constituents in vitro: an SEC-ICP-AES study.
    Pei KL; Gailer J
    Metallomics; 2009 Sep; 1(5):403-8. PubMed ID: 21305144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
    Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
    Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E; Canatan D; Ormeci AR; Vural H; Aylak F
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of deferiprone monotherapy and in combination with deferoxamine for reduction of iron overload in chronically transfused patients with β-thalassemia.
    Kuo KH; Mrkobrada M
    Hemoglobin; 2014; 38(6):409-21. PubMed ID: 25307964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Pagano L; Prossomariti L
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
    Devanur LD; Evans RW; Evans PJ; Hider RC
    Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
    Tubafard S; Fatemi SJ
    Toxicol Ind Health; 2008 May; 24(4):235-40. PubMed ID: 19022876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
    El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
    Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.